Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
BMC Psychiatry
Published in: BMC Psychiatry 1/2013

Open Access 01-12-2013 | Research article

Levels of S100B are raised in female patients with schizophrenia

Authors: Kara O’Connell, Jogin Thakore, Kumlesh K Dev

Published in: BMC Psychiatry | Issue 1/2013

Login to get access

Abstract

Background

The neurotrophic factor, S100B, is released primarily from astrocytes, with serum and CSF levels of S100B reported as altered in schizophrenia. However, many of these reports are contradictory. Here, serum levels of S100B in schizophrenia and influence of age, gender, medication and illness severity were examined.

Methods

Serum S100B levels were measured in patients with schizophrenia treated with clozapine. Lifestyle, metabolic and illness severity parameters were correlated with S100B concentrations.

Results

Data showed raised serum levels of S100B in schizophrenia female patients, but not male patients, compared to controls. Correlation analysis demonstrated a positive association between S100B serum concentrations and BMI.

Conclusions

This study supports previous findings that adipocytes may contribute to S100B serum concentrations in females, in addition to astrocytes. This study also supports the hypothesis that metabolic effects of medication, lifestyle choices and the illness itself, may be contributing factors to altered levels of S100B.
Appendix
Available only for authorised users
Literature
1.
Steiner J, Bogerts B, Schroeter ML: S100B protein in neurodegenerative disorders. Clin Chem Lab Med. 2011, 49: 409-24.CrossRefPubMed
2.
Rothermundt M, Ahn JN, Jörgens S: S100B in schizophrenia: an update. Gen Physiol Biophys. 2009, 28: F76-81.PubMed
3.
Rothermundt M, Ponath G, Arolt V: S100B in schizophrenic psychosis. Int Rev Neurobiol. 2004, 59: 445-70.CrossRefPubMed
4.
Schulte-Herbrüggen O, Hörtnagl H, Ponath G: Distinct regulation of brain-derived neurotrophic factor and noradrenaline in S100B knockout mice. Neurosci Lett. 2008, 442: 100-3. 10.1016/j.neulet.2008.07.013.CrossRefPubMed
5.
Muller N, Schwarz MJ: The immunological basis of glutamatergic disturbance in schizophrenia: towards an integrated view. J Neural Transm Suppl. 2007, 72: 269-80. 10.1007/978-3-211-73574-9_33.CrossRef
6.
Beumer W, Drexhage RC, De Wit H: Increased level of serum cytokines, chemokines and adipokines in patients with schizophrenia is associated with disease and metabolic syndrome. Psychoneuroendocrinology. 2012, In press
7.
Schwarz E, Guest PC, Rahmoune H: Identification of a biological signature for schizophrenia in serum. Mol Psychiatry. 2012, 17: 494-502.1. 10.1038/mp.2011.42.CrossRefPubMed
8.
Leonard BE, Schwarz M, Myint AM: The metabolic syndrome in schizophrenia: is inflammation a contributing cause?. J Psychopharmacol. 2012, 26: 33-41. 10.1177/0269881111431622.CrossRefPubMed
9.
Steiner J, Myint AM, Schiltz K: S100B Serum levels in schizophrenia are presumably related to visceral obesity and insulin resistance. Cardiovasc Psychiatry Neurol. 2010, 2010: 480707-PubMedPubMedCentral
10.
Steiner J, Walter M, Guest P: Elevated S100B levels in schizophrenia are associated with insulin resistance. Mol Psychiatry. 2010, 15: 3-4. 10.1038/mp.2009.87.CrossRefPubMed
11.
Streitbürger DP, Arelin K, Kratzsch J: Validating serum S100B and neuron-specific enolase as biomarkers for the human brain - a combined serum, gene expression and MRI study. PLoS One. 2012, 7: e43284-10.1371/journal.pone.0043284.CrossRefPubMedPubMedCentral
12.
Steiner J, Westphal S, Schroeter ML: Increased S100B + NK cell counts in acutely ill schizophrenia patients are correlated with the free cortisol index, but not with S100B serum levels. Brain Behav Immun. 2012, 26: 564-7. 10.1016/j.bbi.2012.01.018.CrossRefPubMed
13.
Muller N, Schwarz M: Schizophrenia as an inflammation-mediated dysbalance of glutamatergic neurotransmission. Neurotox Res. 2006, 10: 131-48. 10.1007/BF03033242.CrossRefPubMed
14.
Zhai J, Cheng L, Dong J: S100B gene polymorphisms predict prefrontal spatial function in both schizophrenia patients and healthy individuals. Schizophr Res. 2012, 134: 89-94. 10.1016/j.schres.2011.09.029.CrossRefPubMed
15.
Zhai J, Zhang Q, Cheng L: Risk variants in the S100B gene, associated with elevated S100B levels, are also associated with visuospatial disability of schizophrenia. Behav Brain Res. 2011, 217: 363-8. 10.1016/j.bbr.2010.11.004.CrossRefPubMed
16.
Dagdan E, Morris DW, Campbell M: Functional assessment of a promoter polymorphism in S100B, a putative risk variant for bipolar disorder. Am J Med Genet B Neuropsychiatr Genet. 2011, 156B: 691-9.CrossRefPubMed
17.
Suchankova P, Baghaei F, Rosmond R: Genetic variability within the S100B gene influences the personality trait self-directedness. Psychoneuroendocrinology. 2011, 36: 919-23. 10.1016/j.psyneuen.2010.10.017.CrossRefPubMed
18.
Saus E, Brunet A, Armengol L: Comprehensive copy number variant (CNV) analysis of neuronal pathways genes in psychiatric disorders identifies rare variants within patients. J Psychiatr Res. 2010, 4: 971-8.CrossRef
19.
Hohoff C, Ponath G, Freitag CM: Risk variants in the S100B gene predict elevated S100B serum concentrations in healthy individuals. Am J Med Genet B Neuropsychiatr Genet. 2010, 153B: 291-7.PubMed
20.
Roche S, Cassidy F, Zhao C: Candidate gene analysis of 21q22: support for S100B as a susceptibility gene for bipolar affective disorder with psychosis. Am J Med Genet B Neuropsychiatr Genet. 2007, 144B: 1094-6. 10.1002/ajmg.b.30556.CrossRefPubMed
21.
Liu J, Shi Y, Tang J: SNPs and haplotypes in the S100B gene reveal association with schizophrenia. Biochem Biophys Res Commun. 2005, 328: 335-41. 10.1016/j.bbrc.2004.12.175.CrossRefPubMed
22.
Suchankova P, Klang J, Cavanna C: Is the Gly82Ser polymorphism in the RAGE gene relevant to schizophrenia and the personality trait psychoticism?. J Psychiatry Neurosci. 2012, 37: 122-8. 10.1503/jpn.110024.CrossRefPubMedPubMedCentral
23.
Steiner J, Walter M, Wunderlich MT: A new pathophysiological aspect of S100B in schizophrenia: potential regulation of S100B by its scavenger soluble RAGE. Biol Psychiatry. 2009, 65: 1107-10. 10.1016/j.biopsych.2008.10.044.CrossRefPubMed
24.
25.
Zhang XY, Xiu MH, da Chen C: Increased S100B serum levels in schizophrenic patients with tardive dyskinesia: association with dyskinetic movements. J Psychiatr Res. 2010, 44: 429-33. 10.1016/j.jpsychires.2009.10.012.CrossRefPubMed
26.
Steiner J, Bernstein HG, Bielau H: S100B-immunopositive glia is elevated in paranoid as compared to residual schizophrenia: a morphometric study. J Psychiatr Res. 2008, 42: 868-76. 10.1016/j.jpsychires.2007.10.001.CrossRefPubMed
27.
Ryoun Kim H, Kyung Lee M, Park DB: Increased serum S100B protein in chronic schizophrenic patients in Korea. Clin Chem Lab Med. 2007, 45: 1561-3.CrossRefPubMed
28.
Rothermundt M, Ohrmann P, Abel S: Glial cell activation in a subgroup of patients with schizophrenia indicated by increased S100B serum concentrations and elevated myo-inositol. Prog Neuropsychopharmacol Biol Psychiatry. 2007, 31: 361-4. 10.1016/j.pnpbp.2006.09.013.CrossRefPubMed
29.
Steiner J, Bielau H, Bernstein HG: Increased cerebrospinal fluid and serum levels of S100B in first-onset schizophrenia are not related to a degenerative release of glial fibrillar acidic protein, myelin basic protein and neurone-specific enolase from glia or neurones. J Neurol Neurosurg Psychiatry. 2006, 77: 1284-7. 10.1136/jnnp.2006.093427.CrossRefPubMedPubMedCentral
30.
Rothermundt M, Falkai P, Ponath G: Glial cell dysfunction in schizophrenia indicated by increased S100B in the CSF. Mol Psychiatry. 2004, 9: 897-9. 10.1038/sj.mp.4001548.CrossRefPubMed
31.
Wiesmann M, Wandinger KP, Missler U: Elevated plasma levels of S-100b protein in schizophrenic patients. Biol Psychiatry. 1999, 45: 1508-1511. 10.1016/S0006-3223(98)00217-0.CrossRefPubMed
32.
Zhang XY, Xiu MH, Song C: Increased serum S100B in never-medicated and medicated schizophrenic patients. J Psychiatr Res. 2010, 44: 1236-40. 10.1016/j.jpsychires.2010.04.023.CrossRefPubMed
33.
Qi LY, Xiu MH, da Chen C: Increased serum S100B levels in chronic schizophrenic patients on long-term clozapine or typical antipsychotics. Neurosci Lett. 2009, 462: 113-7. 10.1016/j.neulet.2009.06.019.CrossRefPubMed
34.
Schroeter ML, Steiner J: Elevated serum levels of the glial marker protein S100B are not specific for schizophrenia or mood disorders. Mol Psychiatry. 2009, 14: 235-7. 10.1038/mp.2008.85.CrossRefPubMed
35.
Schroeter ML, Abdul-Khaliq H, Krebs M: Neuron-specific enolase is unaltered whereas S100B is elevated in serum of patients with schizophrenia–original research and meta-analysis. Psychiatry Res. 2009, 167: 66-72. 10.1016/j.psychres.2008.01.002.CrossRefPubMed
36.
Pedersen A, Diedrich M, Kaestner F: Memory impairment correlates with increased S100B serum concentrations in patients with chronic schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2008, 32: 1789-92. 10.1016/j.pnpbp.2008.07.017.CrossRefPubMed
37.
Ehrenreich H, Hinze-Selch D, Stawicki S: Improvement of cognitive functions in chronic schizophrenic patients by recombinant human erythropoietin. Mol Psychiatry. 2007, 12: 206-20. 10.1038/sj.mp.4001907.CrossRefPubMed
38.
van Beveren NJ, van der Spelt JJ, de Haan L: Schizophrenia-associated neural growth factors in peripheral blood. A review. Eur Neuropsychopharmacol. 2006, 16: 469-80. 10.1016/j.euroneuro.2006.02.001.CrossRefPubMed
39.
Schmitt A, Bertsch T, Henning U: Increased serum S100B in elderly, chronic schizophrenic patients: negative correlation with deficit symptoms. Schizophr Res. 2005, 80: 305-13. 10.1016/j.schres.2005.04.013.CrossRefPubMed
40.
Rothermundt M, Ponath G, Glaser T: S100B serum levels and long-term improvement of negative symptoms in patients with schizophrenia. Neuropsychopharmacology. 2004, 29: 1004-11. 10.1038/sj.npp.1300403.CrossRefPubMed
41.
Schroeter ML, Abdul-Khaliq H, Frühauf S: Serum S100B is increased during early treatment with antipsychotics and in deficit schizophrenia. Schizophr Res. 2003, 62: 231-6. 10.1016/S0920-9964(02)00383-3.CrossRefPubMed
42.
Lara DR, Gama CS, Belmonte-de-Abreu P: Increased serum S100B protein in schizophrenia: a study in medication-free patients. J Psychiatr Res. 2001, 35: 11-4. 10.1016/S0022-3956(01)00003-6.CrossRefPubMed
43.
Rothermundt M, Missler U, Arolt V: Increased S100B blood levels in unmedicated and treated schizophrenic patients are correlated with negative symptomatology. Mol Psychiatry. 2001, 6: 445-9. 10.1038/sj.mp.4000889.CrossRefPubMed
44.
Gattaz WF, Lara DR, Elkis H: Decreased S100-beta protein in schizophrenia: preliminary evidence. Schizophr Res. 2000, 43: 91-95. 10.1016/S0920-9964(99)00146-2.CrossRefPubMed
45.
Liu Y, Buck DC, Neve KA: Novel interaction of the dopamine D2 receptor and the Ca2+ binding protein S100B: role in D2 receptor function. Mol Pharmacol. 2008, 74: 371-8. 10.1124/mol.108.044925.CrossRefPubMedPubMedCentral
46.
Nardin P, Tramontina AC, Quincozes-Santos A: In vitro S100B secretion is reduced by apomorphine: effects of antipsychotics and antioxidants. Prog Neuropsychopharmacol Biol Psychiatry. 2011, 35: 1291-6. 10.1016/j.pnpbp.2011.04.004.CrossRefPubMed
47.
Herrmann AP, Lunardi P, Pilz LK: Effects of the putative antipsychotic alstonine on glutamate uptake in acute hippocampal slices. Neurochem Int. 2012, In press
48.
Steiner J, Schroeter ML, Schiltz K: Haloperidol and clozapine decrease S100B release from glial cells. Neuroscience. 2010, 167: 1025-31. 10.1016/j.neuroscience.2010.03.010.CrossRefPubMed
49.
Sen J, Belli A: S100B in neuropathologic states: the CRP of the brain?. J Neurosci Res. 2007, 85: 1373-80. 10.1002/jnr.21211.CrossRefPubMed
50.
Steiner J, Bernstein HG, Bielau H: Evidence for a wide extra-astrocytic distribution of S100B in human brain. BMC Neurosci. 2007, 2: 8-2.
51.
Koller E, Schneider B, Bennett K: Clozapine-associated diabetes. Am J Med. 2001, 111: 716-23. 10.1016/S0002-9343(01)01000-2.CrossRefPubMed
52.
American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders. 1994, Washington, DC: American Psychiatric Press, DSM–IV–TR. 4
53.
Woods SW: Chlorpromazine equivalent doses for the newer atypical antipsychotics. J Clin Psychiatry. 2003, 64: 663-667. 10.4088/JCP.v64n0607.CrossRefPubMed
54.
Overall JE, Gorham DR: The brief psychiatric rating scale. Psychol Rep. 1962, 10: 799-812. 10.2466/pr0.1962.10.3.799.CrossRef
55.
Andreasen N: Negative symptoms in schizophrenia. Arch Gen Psychiatry. 1982, 39: 784-788. 10.1001/archpsyc.1982.04290070020005.CrossRefPubMed
56.
Wilson PWF, D’Agostino RB, Levy D: Prediction of coronary heart disease using risk factor categories. Circulation. 1998, 97: 1837-1847. 10.1161/01.CIR.97.18.1837.CrossRefPubMed
57.
Osby U, Correia N, Brandt L: Mortality and causes of death in schizophrenia in Stockholm County, Sweden. Schizophr Res. 2000, 45 (1–2): 21-28.CrossRefPubMed
58.
Spelman LK, Walsh PI, Sharifi N: Impaired glucose tolerance in first-episode drug-naïve patients with schizophrenia. Diabet Med. 2007, 24: 481-485.CrossRefPubMed
59.
Choong E, Bondolfi G, Etter M: Psychotropic drug-induced weight gain and other metabolic complications in a Swiss psychiatric population. J Psychiatr Res. 2012, 46: 540-8. 10.1016/j.jpsychires.2012.01.014.CrossRefPubMed
60.
Hughes JR, Hatsukami DK, Mitchell JE: Prevalence of smoking among psychiatric outpatients. Am J Psychiatry. 1986, 143: 8-
61.
van Engelen BG, Lamers KJ, Gabreels FJ: Age related changes of neuron-specific enolase, S-100 protein, and myelin basic protein concentrations in cerebrospinal fluid. Clin Chem. 1992, 38: 813-816.PubMed
62.
Nygaard O, Langbakk B, Romnera B: Age- and sex-related changes of S-100 protein concentrations in cerebrospinal fluid and serum in patients with no previous history of neurological disorder. Clin Chem. 1997, 43: 541-543.PubMed
63.
Wiesmann M, Missler U, Gottmann D: Plasma S-100b protein concentration in healthy adults is age- and sex-independent. Clin Chem. 1998, 44: 1056-1058.PubMed
64.
Gazzolo D, Michetti F, Bruschettini M: Pediatric concentrations of S100B protein in blood: Age- and Sex-related changes. Clin Chem. 2003, 49: 967-970. 10.1373/49.6.967.CrossRefPubMed
65.
Dev KK, Mullershausen F, Mattes H: Brain S1P receptors: implication for fingolimod in the treatment of multiple sclerosis. Pharmacol Ther. 2008, 117: 77-93. 10.1016/j.pharmthera.2007.08.005.CrossRefPubMed
66.
Gonçalves CA, Leite MC, Guerra MC: Adipocytes as an important source of serum S100B and possible roles of this protein in adipose tissue. Cardiovasc Psychiatry Neurol. 2010, 2010: 790431-PubMedPubMedCentral
67.
Netto CB, Conte S, Leite MC: Serum S100B protein is increased in fasting rats. Arch Med Res. 2006, 37: 683-6. 10.1016/j.arcmed.2005.11.005.CrossRefPubMed
68.
Holtkamp K, Bühren K, Ponath G: Serum levels of S100B are decreased in chronic starvation and normalize with weight gain. J Neural Transm. 2008, 115: 937-40. 10.1007/s00702-008-0041-8.CrossRefPubMed
69.
Barreira TV, Staiano AE, Harrington DM: Anthropometric correlates of total body fat, abdominal adiposity, and cardiovascular disease risk factors in a biracial sample of Men and women. Mayo Clin Proc. 2012, 87 (5): 452-460. 10.1016/j.mayocp.2011.12.017.CrossRefPubMedPubMedCentral
70.
Meltzer HY, Chai BL, Thompson PA: Effect of scopolamine on the efflux of dopamine and its metabolites after clozapine, haloperidol or thioridazine. J. Pharm. Exp. Ther. 1994, 268: 1452-1461.
71.
Konopaske GT, Dorph-Petersen KA, Sweet RA: Effect of chronic antipsychotic exposure on astrocyte and oligodendrocyte numbers in macaque monkeys. Biol Psychiatry. 2008, 63: 759-65. 10.1016/j.biopsych.2007.08.018.CrossRefPubMed
72.
Stanwood GD: Protein-protein interactions and dopamine D2 receptor signaling: a calcium connection. Mol Pharmacol. 2008, 74: 317-9. 10.1124/mol.108.049098.CrossRefPubMed
73.
Hearst SM, Lopez ME, Shao Q: Dopamine D2 receptor signaling modulates mutant ataxin-1 S776 phosphorylation and aggregation. J Neurochem. 2010, 114 (3): 706-16. 10.1111/j.1471-4159.2010.06791.x.CrossRefPubMedPubMedCentral
74.
Dempsey BR, Shaw GS: Identification of calcium-independent and calcium-enhanced binding between S100B and the dopamine D2 receptor. Biochemistry. 2011, 50 (42): 9056-65. 10.1021/bi201054x.CrossRefPubMedPubMedCentral
75.
Liu J, Wang H, Zhang L: S100B transgenic mice develop features of Parkinson’s disease. Arch Med Res. 2011, 42 (1): 1-7. 10.1016/j.arcmed.2011.01.005.CrossRefPubMed
Metadata
Title
Levels of S100B are raised in female patients with schizophrenia
Authors
Kara O’Connell
Jogin Thakore
Kumlesh K Dev
Publication date
01-12-2013
Publisher
BioMed Central
Published in
BMC Psychiatry / Issue 1/2013
Electronic ISSN: 1471-244X
DOI
https://doi.org/10.1186/1471-244X-13-146

Other articles of this Issue 1/2013

BMC Psychiatry 1/2013 Go to the issue

Study protocol

Preventing the onset of major depression based on the level and profile of risk of primary care attendees: protocol of a cluster randomised trial (the predictD-CCRT study)

Research article

Screening high-risk patients and assisting in diagnosing anxiety in primary care: the Patient Health Questionnaire evaluated

Research article

A 6-month randomized controlled trial to test the efficacy of a lifestyle intervention for weight gain management in schizophrenia

Research article

Gender differences in first episode psychotic mania

Research article

Using the mood disorder questionnaire and bipolar spectrum diagnostic scale to detect bipolar disorder and borderline personality disorder among eating disorder patients

Research article

A day-by-day investigation of changes in criminal convictions before and after entering and leaving opioid maintenance treatment: a national cohort study